Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

被引：62
|
作者：
Gadgeel, Shirish M.
Stevenson, James
Langer, Corey J.
Gandhi, Leena
Borghaei, Hossein
Patnaik, Amita
Villaruz, Liza Cosca
Gubens, Matthew A.
Hauke, Ralph J.
Yang, James Chih-Hsin
Sequist, Lecia V.
Bachman, Robert D.
Ge, Joy Yang
Raftopoulos, Harry
Papadimitrakopoulou, Vassiliki
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[6] South Texas Accelerated Res Theraput, San Antonio, TX USA
[7] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Nebraska Canc Specialists, Omaha, NE USA
[10] Natl Taiwan Univ Hosp, Taipei, Taiwan
[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[12] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[13] Harvard Med Sch, Boston, MA 02115 USA
[14] Merck & Co Inc, Kenilworth, NJ USA
[15] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.9016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9016
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase III Study of Front-Line Chemotherapy with TTFields for Advanced Squamous NSCLC
    Farber, Ori
    Weinberg, Uri
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S668 - S668
  • [22] KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
    Gadgeel, S.
    Rodriguez-Abreu, D.
    Felip, E.
    Esteban, E.
    Speranza, G.
    Reck, M.
    Hui, R.
    Boyer, M.
    Garon, E. B.
    Horinouchi, H.
    Cristescu, R.
    Aurora-Garg, D.
    Lunceford, J.
    Kobie, J.
    Ayers, M.
    Piperdi, B.
    Pietanza, M. C.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2019, 30 : 64 - 65
  • [23] Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
    Gadgeel, Shirish
    Gandhi, Leena
    Borghaei, Hossein
    Socinski, Mark A.
    Gubens, Matthew A.
    Stevenson, James
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    Papadimitrakopoulou, Vassiliki
    Bourque, Jennifer
    Bachman, Robert D.
    Ge, Joy Yang
    Im, Ellie
    Patnaik, Amita
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S428 - S428
  • [24] KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment
    Cummings, Amy Lauren
    Santoso, Kate M.
    Goldman, Jonathan W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 706 - 709
  • [25] LUNAR: Phase III study of front-line chemotherapy with TTFields for advanced squamous NSCLC
    Weinberg, U.
    Farber, O.
    Giladi, M.
    Bomzon, Z.
    Kirson, E. D.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S141 - S141
  • [26] Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.
    Chiara Garassino, Marina
    Gadgeel, Shirish M.
    Rodriguez-Abreu, Delvys
    Felip, Enriqueta
    Esteban, Emilio
    Speranza, Giovanna
    Hochmair, Maximilian
    Francis Powell, Steven
    Garon, Edward B.
    Hui, Rina
    Nogami, Naoyuki
    Cristescu, Razvan
    Morrissey, Michael
    Loboda, Andrey
    Kobie, Julie
    Ayers, Mark
    Piperdi, Bilal
    Catherine Pietanza, Maria
    Snyder, Alexandra
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC
    Awad, M. M.
    Gadgeel, S. M.
    Borghaei, H.
    Patnaik, A.
    Yang, J. Chih-Hsin
    Powell, S. F.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Altan, M.
    Jalal, S. I.
    Panwalkar, A.
    Gubens, M.
    Sequist, L. V.
    Saraf, S.
    Zhao, B.
    Piperdi, B.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S8 - S8
  • [28] Pembrolizumab (pembro) plus binimetinib (bini) with or without chemotherapy (chemo) for metastatic colorectal cancer (mCRC): Results from KEYNOTE-651 cohorts A, C, and E.
    Chen, Eric Xueyu
    Kavan, Petr
    Tehfe, Mustapha
    Kortmansky, Jeremy S.
    Sawyer, Michael B.
    Chiorean, E. Gabriela
    Lieu, Christopher Hanyoung
    Polite, Blase N.
    Wong, Lucas
    Fakih, Marwan
    Spencer, Kristen Renee
    Chaves, Jorge
    Li, Chenxiang
    Carpenter, David
    Leconte, Pierre
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799
    Reck, M.
    Lee, K. H.
    Frost, N.
    Kowalski, D. M.
    Breder, V.
    Pollock, T.
    Reguart, N.
    Houghton, B.
    Quantin, X.
    Keller, S. M.
    Liu, H.
    Piperdi, B.
    Jabbour, S. K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S103 - S104
  • [30] Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy for Unresectable, Locally Advanced, Stage 3 NSCLC: KEYNOTE-799
    Jabbour, S. K.
    Lee, K. H.
    Frost, N.
    Breder, V.
    Kowalski, D.
    Alawin, I.
    Levchenko, E.
    Reguart, N.
    Martinez-Marti, A.
    Houghton, B.
    Paoli, J. B.
    Safina, S.
    Park, K.
    Komiya, T.
    Sanford, A.
    Boolell, V.
    Liu, H.
    Samkari, A.
    Keller, S.
    Reck, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S9 - S10
12345